Merck Group

?? NEWS: Positive Results for TGCT Patients in Global Phase III Study ?? An investigative treatment being developed by our partner 和誉医药 Abbisko Therapeutics shows potential to meet unmet needs for patients with Tenosynovial Giant Cell Tumor (TGCT). ?? Read more here: https://lnkd.in/eFsDr8kM #AsOneForPatients #PhaseIII #TGCT #Oncology

Today marks an exciting milestone for us as we welcome UnitySC into our family, expanding our portfolio with world-class #metrology and #inspection tools. This acquisition is a result of our commitment to advancing digital living by unlocking next-generation chips and devices through the convergence of optical and semiconductors. Together, we’ll deliver breakthroughs that empower our customers and shape the future of electronics. In pursuit of shaping the future of Electronics, we are also excited to announce that our Display business will operate under the name #Optronics in future, symbolizing our expanded focus on harnessing the transformative power of light to reshape electronic devices and systems. This strategic shift strengthens our position at the intersection of semiconductor and optical technologies, allowing us to push boundaries in #AI chip innovation. Learn more about our acquisition of UnitySC and strategic focus here: https://lnkd.in/gNYACeJW? #Acquisition Merck Group

Exciting news! We’re investing €70 million to triple our Antibody-Drug Conjugate (ADC) manufacturing capacity in St. Louis, Missouri. This expansion reinforces our commitment to advancing these cutting-edge novel therapies, and to our clients and ultimately patients. ADCs precisely target cancer cells, sparing healthy ones—one of the most promising advances in cancer treatment today. Together with our clients, we’re unlocking ADCs’ full potential to impact life and health with science. Learn more here: https://ms.spr.ly/6045W3d5U

We are honored to share that we have been awarded the 3Rs Prize by National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) pioneering non-animal method with regulatory approval for evaluating hormone potency. This annual prize is awarded for papers showing outstanding, original work with significant potential to impact the 3Rs—replacement, reduction, or refinement—of animal use in research. This recognition is a testament to our commitment to advancing ethical and sustainable research. A special congratulations to Francesco Nevelli, Head of Cell Based Assay Lab - Senior Scientist and his team, for exceptional work in developing the in vitro assay to test follicle-stimulating hormone potency. This shall reduce the use of tens of thousands of animals in testing annually, marking an important step forward in humane research. Learn more about our award-winning research here: https://lnkd.in/ej86XbVN #3RsPrize #InVitro #Research #Pioneering #Alternativestoanimaltesting

Ad-hoc release: We have raised our forecast for 2024. Find more information: https://lnkd.in/eF9DHgqJ #adhoc

Big news! Today, we announced the opening of our newly expanded Life Science distribution center in Schnelldorf, Germany. The investment of € 180 million added 25,000 square meters to the site, almost doubling its size. It now includes a new manual down filling operation and additional space for the distribution of a wide range of products to laboratories and research facilities all around the world. Congratulations to the team! Merck Life Science

Thank you for putting a big smile on our face today!??????

Merck has signed a definitive agreement to acquire life science company Mirus Bio for US$ 600 million (around € 550 million). Mirus Bio is a specialist in the development and commercialization of transfection reagents. These reagents play a key role in the production of viral vectors for cell and gene therapies. The acquisition will advance our integrated offering for viral vector manufacturing and complements the existing portfolio for development and production of novel modalities – a key growth area for Merck Life Science. More: https://lnkd.in/eeF5HfRf [?? from our Carlsbad, California manufacturing facility]

In recent conversations with my family, colleagues, and industry peers in Germany but also across Europe, there has been one recurring topic – we are all witnessing an alarming rise of populism, protectionism, and a decline in solidarity. A recent Global Risk Report 2024 launched by the World Economic Forum highlighted 'societal polarization' as one of the top global risks facing our world. This underscores the urgency to unite, consider the bigger picture, work in support of international collaboration, while respecting and role-modeling our democratic principles. And these shouldn’t be negotiable. My aspiration for an inclusive world starts with upholding our commitment to core European values. Democracy, freedom, equality, and human rights are and must remain the core of our identity. These values are not only the foundation of our society but also provide the fertile ground for innovation, growth, and competitiveness. The key here is to further nurture the power of diversity to build a stronger and more united Europe.?

As 2023 draws to a close, we want to take a moment to look back at a year of transformation and progress, and the achievements that characterized 2023 and will continue to shape our work in the future.?We want to say thank you to our community, our employees and all the people who share our love and passion for science and technology. ? ?? Join us in revisiting the highlights of 2023 in this article! ? #2023 #YearEnd #Recap